Skip to main content
Caplight Logo









ThinkCyte

ThinkCyte

Private
TokyoHealthcare & Life Scienceshttps://thinkcyte.com/

Last Round

Grant

Aug 4, 2025

Total Funding Raised

$129.9M

Company Overview

ThinkCyte is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Medical AI, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Services & Consulting

AI Layer

Application

Keywords

cell sortingghost cytometrylabel-free analysismorphological profilingsingle-cell analysisAI-driven cytometrybiotech hardwaredrug discovery toolscell therapy developmentmicrofluidicssmart lab equipmentdigital pathologyhigh-throughput screeninglab automationAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ThinkCyte Comparables

Compare ThinkCyte with similar companies based on industry and business-model similarity.

ThinkCyte comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Deepcell
94%
NanoCellect Biomedical
81%
STEMCELL Technologies
81%

ThinkCyte Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 4, 2025
Series CAug 29, 2024
DebtAug 29, 2024
GrantNov 28, 2023
Series CNov 28, 2023
Grant
Oct 18, 2023

Key People

Founding team and executive leadership

Hikaru Nagahori

COO & President of ThinkCyte North America

Executive Team

Ryo Otsuki

CFO

Executive Team

Keiji Nakagawa

Chief Product Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 29, 2025

    Added Almog Diagnostic & Medical Equipment Ltd. as a customer.

  • Jun 3, 2025

    Launched MorphoScan Cloud, a cloud-based platform for AI-driven cell morphology analysis.

ThinkCyte Filings

Explore SEC and related filing metadata, where available.

ThinkCyte filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ThinkCyte's valuation, stock price, and market status.

Is ThinkCyte a public or private company?

ThinkCyte is a private company.

What is the current stock price of ThinkCyte?

ThinkCyte is a private company with no public stock price. No recent secondary market data is available.

How much is ThinkCyte worth (valuation)?

Valuation information for ThinkCyte is not publicly available.

Can I buy ThinkCyte stock?

ThinkCyte shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ThinkCyte's last funding round?

ThinkCyte's most recent funding round was Grant on August 4, 2025.

Who are the main investors in ThinkCyte?

Key investors in ThinkCyte include Japan Agency for Medical Research and Development, 株式会社日本政策金融公庫, Global Brain Corporation, JAPAN GREEN INVESTMENT CORP. FOR CARBON NEUTRALITY (JICN), SPARX Group.

Will ThinkCyte IPO soon?

No public IPO plans have been announced for ThinkCyte.

How can I track ThinkCyte secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ThinkCyte's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTokyo
Employee Range48
Year Founded2016
Last FundingAug 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?